Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo controlled, phase IIA study to assess the effect on GERD [gastro-esophageal reflux disease] symptoms, PK [pharmacokinetics], safety and tolerability of 4 weeks treatment with AZD3355 65 mg bid [twice daily] as add-on treatment to a PPI [proton pump inhibitor] in patients with an incomplete response to PPI

Next Previous
X
Search
Trial Profile

A randomized, double-blind, placebo controlled, phase IIA study to assess the effect on GERD [gastro-esophageal reflux disease] symptoms, PK [pharmacokinetics], safety and tolerability of 4 weeks treatment with AZD3355 65 mg bid [twice daily] as add-on treatment to a PPI [proton pump inhibitor] in patients with an incomplete response to PPI

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lesogaberan (Primary) ; Proton pump inhibitors
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

    • Most Recent Events

    • 18 May 2011 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
    • 25 Nov 2009 Primary endpoint 'Clinical response' has been met.
    • 25 Nov 2009 Results reported at Gastro 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top